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Rev-erb is an orphan nuclear receptor that selec-
tively blocks trans-activation mediated by the retinoic
acid-related orphan receptor- (ROR). ROR has been
implicated in the regulation of high density lipoprotein
cholesterol, lipid homeostasis, and inflammation. Rev-
erb and ROR are expressed in similar tissues, includ-
ing skeletal muscle; however, the pathophysiological
function of Rev-erb has remained obscure. We hypoth-
esize from the similar expression patterns, target genes,
and overlapping cognate sequences of these nuclear re-
ceptors that Rev-erb regulates lipid metabolism in
skeletal muscle. This lean tissue accounts for >30% of
total body weight and 50% of energy expenditure. More-
over, this metabolically demanding tissue is a primary
site of glucose disposal, fatty acid oxidation, and choles-
terol efflux. Consequently, muscle has a significant role
in insulin sensitivity, obesity, and the blood-lipid pro-
file. We utilize ectopic expression in skeletal muscle
cells to understand the regulatory role of Rev-erb in
this major mass peripheral tissue. Exogenous expres-
sion of a dominant negative version of mouse Rev-erb
decreases the expression of many genes involved in fatty
acid/lipid absorption (including Cd36, and Fabp-3 and
-4). Interestingly, we observed a robust induction (>15-
fold) in mRNA expression of interleukin-6, an “exercise-
induced myokine” that regulates energy expenditure
and inflammation. Furthermore, we observed the dra-
matic repression (>20-fold) ofmyostatinmRNA, another
myokine that is a negative regulator of muscle hyper-
trophy and hyperplasia that impacts on body fat accu-
mulation. This study implicates Rev-erb in the control
of lipid and energy homoeostasis in skeletal muscle. In
conclusion, we speculate that selective modulators of
Rev-erb may have therapeutic utility in the treatment
of dyslipidemia and regulation of muscle growth.
Members of the nuclear receptor (NR)1 superfamily bind to
specific DNA elements and function as transcriptional regula-
tors (1, 2). In addition to the ligand-activated NRs, many mem-
bers within this superfamily have no known ligand, and are
referred to as “orphan NRs” (3). The orphan receptor Rev-erb
(NR1D2, also known as Rev-erb-related receptor, RVR) be-
longs to the family of “Reverbs” that also contain Rev-erb (4,
5). The primary structure of these two receptors together with
retinoic acid-related orphan receptor- (ROR) and the Dro-
sophila orphan receptor, E75A, is very similar especially in the
DNA-binding domain and the putative ligand-binding domain
(6).
Two Rev-erb genes have been identified; Rev-erb1 and
Rev-erb2, which are alternatively spliced products of the Rev-
erb gene (7). The mRNA expression data shows that Rev-erb
is abundantly expressed in most tissues, although higher levels
of expression are observed in skeletal muscle, brain, kidney,
and liver (Refs. 4 and 8 and references therein).
Rev-erb, Rev-erb, and ROR bind as monomers to the nu-
clear receptor half-site motif, PuGGTCA flanked 5 by an AT-
rich sequence ((A/T)6PuGGTCA). Although these receptors are
closely related, and bind to the same motif, they function in an
opposing manner. Whereas ROR activates gene transcription,
Rev-erb and Rev-erbmediate transcriptional repression, and
can repress trans-activation mediated by ROR (6, 9–12). The
inter-relationship between these nuclear receptors is under-
scored by the evidence that demonstrates ROR trans-acti-
vates the Rev-erb promoter (13).
Loss of function studies in cell culture and in animal models
has demonstrated a role of ROR in lipid metabolism. ROR-
deficient staggerer mice are predisposed to the development of
atherosclerosis. The staggerer mice possess an aberrant blood-
lipid profile with low circulating levels of major lipoproteins
such as HDL cholesterol, apolipoprotein (apo) C-III, and
plasma triglycerides. Furthermore, decreases in specific apoli-
poprotein compartments, namely Apoa-I, the major constituent
of HDL, and Apoa-II that lead to hypo--lipoproteinemia have
been reported in staggerer mice (15). Moreover, our recent
studies demonstrate that ROR regulates the expression of
genes involved in lipid homeostasis and energy balance in
skeletal muscle cells (16).
Several reports have demonstrated the role of Rev-erb in
lipid metabolism and inflammation. In the context of lipid
metabolism, Rev-erb, together with peroxisome proliferator
activated receptor- (PPAR-) has been shown to regulate the
expression of ApoA1 in a species-specific manner (17). Apoa1
has an important role in the formation of nascent HDL parti-
cles and apolipoprotein-mediated cholesterol efflux in mice (18,
19). Furthermore, Rev-erb has also been shown to regulate
the expression of the ApoC-III gene that plays a key role in
maintaining serum triglyceride levels (20, 21). The inter-rela-
tionship between Rev-erb and lipid metabolism has not been
investigated. Within inflammatory pathways, Rev-erb and
ROR act opposingly on the NFB pathway. ROR has been
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shown to directly up-regulate the expression of IB, the major
inhibitor of the NFB signaling pathway by binding to the IB
promoter (22). The functional role of Rev-erb in NFB-medi-
ated inflammation still remains obscure.
Rev-erb is abundantly expressed in skeletal muscle and
brown fat. Skeletal muscle is one of the most metabolically
demanding major mass peripheral tissues that accounts for
50% of energy expenditure. Moreover, this lean tissue relies
heavily on fatty acids as an energy source, accounts for 75% of
glucose disposal, and is involved in cholesterol efflux. Conse-
quently, muscle has a significant role in insulin sensitivity and
the blood-lipid profile. However, the role of Rev-erb in skeletal
muscle lipid and energy homeostasis has not been well studied.
The C2C12 in vitro cell culture model system has been used
to investigate the regulation of lipid metabolism and choles-
terol homeostasis by nuclear receptors such as LXR (23),
PPAR, -/, - (24–28), and ROR (16). Selective and syn-
thetic agonists to these nuclear receptors induce similar effects
on mRNAs encoding Abca1/g1, ApoE, sterol regulatory ele-
ment-binding protein (Srebp)-1c, Scd-1, Fabp3, fatty acid syn-
thase, lipoprotein lipase, Glut5, Ucp-2, and Ucp-3 in differen-
tiated C2C12-myotubes and Mus musculus skeletal muscle
tissue (23–25). The physiological validation of the cell culture
model with respect to lipid homeostasis in the mouse corrobo-
rates the utility of this model system. This cell culture model
provides an ideal platform to identify the Rev-erb-dependent
regulation of genes involved in metabolism.
We have examined the regulation of gene expression in-
volved in lipid homeostasis by Rev-erb “loss of function” in
skeletal muscle cell culture model. Our investigation demon-
strates that Rev-erb controls the expression of genes involved
in lipid absorption. Moreover, we observed the regulation of
genes encoding critical myokines that influence energy expend-
iture and inflammation.
MATERIALS AND METHODS
Cell Culture—Mouse myogenic C2C12 cells were cultured in growth
medium (Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated Serum Supreme (BioWhittaker, Edward Keller Pty.
Ltd., Hallam, Victoria, Australia)) in 6% CO2. Myoblasts were differen-
tiated into post-mitotic multinucleated myotubes by 4 days of serum
withdrawal (i.e. cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 1% fetal calf serum  1% serum supreme). Cells were
harvested 96 h (4 days) after mitogen withdrawal.
C2C12 Transfections—Each well of a 24-well plate of C2C12 cells
(50% confluence) was transfected with DNA using the liposome-me-
diated transfection procedure as described previously (16). Cells were
transfected using a DOTAP and Metafectene (Biontex Laboratories
GmbH, Munich, Germany) liposome mixture in 1 HBS (HEPES-buff-
ered saline (42 mM HEPES, 275 mM NaCl, 10 mM KCl, 0.4 mM
Na2HPO4, 11 mM dextrose (pH 7.1)). The DNA/DOTAP/Metafectene
mixture was added to the cells in 0.6 ml of Dulbecco’s modified Eagle’s
medium supplemented with 5% fetal calf serum for experiments with
ROR or 10% serum supreme. After 16–24 h, the culture medium was
changed and after a further 24 h the cells were harvested for the assay
of luciferase activity. Luciferase activity was measured as described
previously (16).
C2:Rev-erbE Stably Transfected Cell Line—The transfection of
pSG5-Rev-erbE into mouse myogenic C2C12 cells and the selection
of stably transfected polyclonal cells using G418 has been described
previously (29). The cells were cultured in growth medium with G418,
and differentiated into post-mitotic multinucleated myotubes by 4 days
of serum withdrawal.
RNA Extraction and cDNA Synthesis—Total RNA was extracted
from C2C12 cells using Tri-Reagent (Sigma) according to the manufac-
turer’s protocol. After treatment with 2 units of Turbo DNase (Ambion,
Austin, TX) for 60 min, DNase was inactivated by heating to 75 °C for
10 min. RNA for quantitative real time (Q-RT)-PCR was further puri-
fied using the RNeasy RNA extraction kit (Qiagen, Clifton Hill, Victo-
ria, Australia) according to the manufacturer’s instructions.
Q-RT-PCR—RNA was normalized using UV spectrometry and aga-
rose gel electrophoresis. Complementary DNA was synthesized from 3
FIG. 1. Q-RT-PCR analysis of mRNA expression during skele-
tal muscle myogenesis. Total RNA from wild type C2C12 proliferat-
ing myoblasts (PMB), and myotubes after 4 days of serum withdrawal
(MT4) was reverse transcribed to cDNA and analyzed by Q-RT-PCR.
Gene-specific primers were used to examine the expression of: A, Rev-
erb; B, Tnni1; C, Tnni2; D, myogenin; E, lipoprotein lipase; F, ROR;
G, Fat/Cd36; H, Fabp3; I, Fabp4; J, Scd-1; K, Ucp-3; L, Ucp-2; M,
Srebp1c; and N, AdipoR2. Normalized expression is relative to the
expression of 18S rRNA determined with the same cDNA then multi-
plied by 10,000. All reactions were performed in triplicate and results
are shown as average  S.D.
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g of total RNA using Superscript III Reverse Transcriptase (Invitro-
gen Australia Pty. Ltd., Mulgrave, Victoria, Australia) and random
hexamers according to the manufacturer’s instructions. Target cDNA
levels were analyzed by Q-RT-PCR in 25-l reactions containing either
SYBR green (ABI, Warrington, UK) or Taqman PCR master mix (ABI,
Branchburg, NJ), 200 nM each of forward and reverse primers or As-
says-on-Demand Taqman primers (ABI, Foster City, CA), and cDNA
(derived from 50 nanograms of RNA) by using an ABI Prism 7000
Sequence Detector system. PCR was conducted over 45 cycles at 95 °C
for 15 s and 60 °C for a 1-min two-step thermal cycling preceded by an
initial 95 °C for 10 min for activation of Amplitaq Gold DNA
polymerase.
Primers—Primers used for the Q-RT-PCR analysis of the mRNA
populations have been described in detail (16), with the exception of
primers designed for the detection of Rev-erbE (pSG5-RVR-F, TGG-
GCAACGTGCTGGTTA; pSG5-RVR-R, CCATGGTGGGATCCGAATT),
Mcad (MCAD-F, CAGCCAATGATGTGTGCTTACTG; MCAD-R, ATA-
ACATACTCGTCACCCTTCTTCTCT), Err (ERR-F, CTCTGGCTAC-
CACTACGGTGTG; ERR-R, AGCTGTACTCGATGCTCCCCT), IL-6 (I-
L-6-F, AGCCAGAGTCCTTCAGA; IL-6-R, GGTCCTTAGCCACTCCT)
using SYBR green. Rev-erb, Fabp4, NFB (relA), IB, Cox-2, IL-15,
andmyostatinwere detected using Assay-on-demand primer/probe sets.
Plasmids—pSG5, pSG5-Rev-erb, and pSG5-Rev-erbE have been
described previously (29). The reporters containing the human Rev-
erbA promoter (pRev-erbAWT) or four copies of the mouse Purkinje
cell protein-2 RORE (mPCP-2tk LUC) linked to the luciferase gene have
been described previously (9, 16).
RESULTS
Rev-erb mRNA Is Expressed in Skeletal Muscle Cells and
Repressed during Myogenic Differentiation—Many studies in-
dicate that the C2C12 cell line is an excellent cell culture model
to investigate myogenesis, and the NR-mediated regulation of
lipid homeostasis in skeletal muscle (23–26). In this culture
system, proliferating C2C12 myoblasts can be induced to bio-
chemically and morphologically differentiate into post-mitotic
multinucleated myotubes by serum withdrawal in culture over
a 48–96-h period. This transition from a non-muscle phenotype
to a contractile phenotype is associated with activation/expres-
sion of a structurally diverse group of genes responsible for
contraction and the extreme metabolic demands on this tissue.
Initially, total RNA was isolated from proliferating myo-
blasts and post-mitotic myotubes after 4 days of serum with-
drawal, converted to cDNA for the analysis of mRNA expres-
sion by Q-RT-PCR. We utilized the GenBankTM sequences of
mouse Rev-erb to design specific primers for detection of
mouse Rev-erb by Q-RT-PCR.
We observed that Rev-erb is expressed in proliferating myo-
blasts and the transcript was decreased 2–3-fold as the cells
exit the cell cycle and form differentiated multinucleated myo-
tubes (Fig. 1A). Concomitant with this decrease in Rev-erb
mRNA was the striking induction of expression of mRNA that
encodes the slow (type I, Tnni1) and fast (type II, Tnni2)
isoforms of the contractile protein, troponin I, and myogenin
that encodes the hierarchical basic helix loop helix regulator
(Fig. 1, B–D). These data confirmed that these cells had termi-
nally differentiated and had acquired a contractile phenotype.
TABLE I
Key target genes in this study
Metabolic genes
Abca1 and Abcg8 ATP binding cassette proteins: transporters that transfer cholesterol to the HDL acceptors, i.e. reverse
cholesterol efflux
Acs4 Acyl-CoA synthetase-4. Enhances the uptake of fatty acids by catalyzing their activation to acyl-CoA esters
for subsequent use in catabolic fatty acid oxidation pathways.
Adrp/adipophilin Adipocyte differentiation-related protein. Involved in lipid storage.
AdipoR1 and R2 Adiponectin receptors 1 and 2. Cell surface membrane receptors for adiponectin that regulate glucose uptake
and fatty acid oxidation.
Ampk 5AMP-activated protein kinase. A fuel-sensing enzyme that responds to cellular stress by regulating
carbohydrate and fat metabolism.
ApoE Apolipoprotein-E: facilitates cholesterol and lipid efflux.
Cav3 Caveolin 3. Muscle-specific caveolin involves in membrane protein anchoring, caveolae, t-tubules formation
and lipid trafficking.
Cpt-1 and -2 Carnitine palmitoyltransferases. Transfers the long-chain fatty acyl group from coenzyme A to carnitine, the
initial reaction of mitochondrial import of long-chain fatty acids and their subsequent oxidation.
Fas Fatty acid synthase. Involved in de novo fatty acid production.
Fat and Fabp3/Fabp4 Fatty acid translocase, and fatty acid-binding proteins. Facilitate uptake of long chain fatty acids (LFCAs)
and low density lipoproteins (LDLs).
Lpl Lipoprotein lipase. Hydrolysis of lipoprotein triglycerides into free fatty acids and responsible for the uptake
of free fatty acids.
Mcad Medium chain acyl coenzyme A dehydrogenase. A key enzyme involved in fatty acid oxidation pathway.
Pdk-2 and -4 Pyruvate dehydrogenase kinases: inhibiting the pyruvate dehydrogenase complex, thereby controlling
glucose oxidation and maintaining pyruvate for gluconeogenesis.
Scd-1 and -2 Stearoyl CoA desaturase-1, and -2. Enzymes associated with adiposity, i.e. storage and esterification of
cholesterol, and responsible for the cis saturation of stearoyl and palmitoyl-CoA converting them to oleate
and palmitoleate, which are the monounsaturated fatty acids of triglycerides.
Srebp-1c Sterol regulatory element-binding protein-1c, the hierarchical transcriptional activator of lipogenesis.
Ucp-2 and -3 Uncoupling proteins. Mitochondrial proteins that uncouple metabolic fuel oxidation from ATP-synthesis,
regulating energy expenditure.
Myokines and inflammatory mediators
IL-6 Interleukin-6. An inflammatory cytokine and exercise induced myokine. A key gene that acts as functional
link between inflammation and metabolism.
IL-15 Interleukin-15. An inflammatory cytokine. Stimulates skeletal muscle fiber protein synthesis. Inhibits fat
deposition in vivo in muscle.
IB Inhibitor of NFappaB . A cytoplasmic protein. Regulates the expression of inflammatory genes through
interaction with NFB.
Cox-2 Cyclooxygenase-2. An inflammatory protein. Involved in the synthesis of prostaglandin-H upon tumor
necrosis factor stimulation. Also plays role in regulating blood pressure.
Myostatin Member of the transforming growth factor  family. Operates as a negative regulator of skeletal muscle
mass.
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Furthermore, we analyzed the expression of several genes
that encode major metabolic enzymes and regulators that are
involved in the regulation of energy expenditure and lipid
homeostasis (as described in Table I). Acquisition of the mus-
cle-specific phenotype saw an increase in expression of mRNAs
encoding lipoprotein lipase (Fig. 1E), ROR (Fig. 1F), fatty acid
translocase/CD36 (Fat/Cd36, Fig. 1G), fatty acid binding pro-
teins 3 and 4 (Fig. 1, H and I), and the uncoupling proteins
(Ucp2 and -3, Fig. 1, K and L). Finally, there was no change in
the expression of the mRNAs encoding Srebp-1c (Fig. 1M),
stearoyl-CoA desaturase 1 (Scd-1, Fig. 1J), and adiponectin
receptor 2 (adipoR2, Fig. 1N).
In summary, these data demonstrate that the mRNA tran-
script encoding Rev-erb was expressed during myogenesis.
Second, during the acquisition of a contractile and metabolic
phenotype (consistent with the increased utilization of lipids in
skeletal muscle) we observed an 2.5-fold repression of this
orphan NR. However, we note that Rev-erb is still expressed
at a significant level in differentiated cells, in concordance with
the expression of this orphan NR in adult muscle tissue.
Deletion of the Rev-erb Ligand Binding Domain Compro-
mises Its Ability to Repress ROR-mediated Trans-activa-
tion—To understand the metabolic role of Rev-erb in skele-
tal muscle lipid and energy homeostasis, and to identify
target genes of this orphan receptor in muscle cells, we ex-
amined the effect of perturbing Rev-erb function. To disrupt
Rev-erb-mediated trans-repression of gene expression, we
utilized Rev-erbE, that encodes amino acids 1–394 but
lacks the entire E region that encodes the putative ligand
binding domain of Rev-erb. Deletion of this region has been
reported to have a dominant negative effect on Rev-erb-
mediated trans-repression of gene expression (29). Moreover,
this region has been implicated in associating with the nu-
clear receptor co-repressors (30). In transient transfection
assays in C2C12 skeletal muscle cells, deletion of the E
region ablated the ability of Rev-erb to trans-repress the
human Rev-erbA promoter (Fig. 2A). Moreover, the capacity
of Rev-erb to repress ROR-mediated transcription is dimin-
ished when the E region is absent (Fig. 2, B and C). This
demonstrates that deletion of the E-region that encodes the
ligand binding domain of Rev-erb compromises the capacity
of this orphan NR to trans-repress the Rev-erb promoter,
and to attenuate ROR-mediated trans-activation.
Ectopic Dominant Negative (Rev-erbE) Expression Induces
Precocious Differentiation and ROR mRNA Expression—The
stable C2C12 cell line expressing Rev-erbE (C2:Rev-erbE)
has been described previously (29). Prior to more extensive
analysis of this cell line, we decided to ascertain the Rev-erb
status of this cell line. We designed a SYBR green-mediated
Q-RT-PCR assay to selectively detect the ectopically expressed
Rev-erbE transcript. We observed that the C2:Rev-erbE
cell line specifically expresses the ectopically introduced mRNA
in myoblasts and myotubes (Fig. 3, A and B). The expression of
the exogenous transcript is constitutive (Fig. 3, A and B) in
contrast to the endogenous transcript that is down-regulated
during differentiation of proliferating myoblasts to postmitotic
myotubes (Fig. 1A). Moreover, the steady state levels of myo-
genin mRNA were elevated in myotubes from the C2:Rev-
erbE cell line relative to wild-type C2C12 cells (Fig. 3C).
This is consistent with the previously reported precocious bio-
chemical and morphological differentiation of the C2:Rev-
erbE cell line relative to wild-type C2C12 cells (29). For
example, Burke et al. (29) reported induction of differentiation
upon serum withdrawal leads to accelerated activation and
expression of the myogenin, and p21Cip-1/Waf-1 mRNAs. More-
over, reduced expression of cyclin D1 was observed, which
FIG. 2. Deletion of the E region of Rev-erb compromises its
trans-repression activity. A, C2C12 cells were co-transfected with
0.5 g of the reporter, pRev-erbAWT, and 0.16 g each of pSG5,
pSG5-Rev-erb, and pSG5-Rev-erbE. -Fold repression is expressed
relative to luciferase activity obtained after co-transfection of the re-
porter and pSG5 vector only, arbitrarily set at 1. All transfections
comprised six replicates and results are shown as average  S.D. B,
C2C12 cells were co-transfected with 0.33 g of the ROR responsive
reporter, mPCP-2tk-LUC, and 0.48 g of pSG5 or 0.16 g of pSG5-
ROR and increasing amounts (0.05, 0.1, and 0.2 g) of pSG5-Rev-erb
or pSG5-Rev-erbE. pSG5 was added to normalize the final amount of
DNA transfected to 0.63 g in each well. All transfections comprised six
replicates and results are shown as average  S.D. C, data from B are
represented in terms of -fold repression. -Fold repression is expressed
relative to luciferase activity obtained after co-transfection of the re-
porter and pSG5-ROR, arbitrarily set at 1.
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correlated with the increased expression of the cdk inhibitor,
p21 (29). In addition, the levels of the non-muscle cytoskeletal
-actin are repressed in the C2:Rev-erbE cell line, relative to
wild-type C2C12 cells (Fig. 3D) in concordance with the ele-
vated myogenin mRNA and precocious differentiative capacity
of this cell line (29).
We used Q-RT-PCR with an ABI Taqman primer set that
does not discriminate between ectopic Rev-erbE and endog-
enous Rev-erb mRNA expression to determine the total quan-
tity of Rev-erb mRNA in the stable cell line. We observed that
the total pool of Rev-erb mRNA is increased by 20–30% in
myotubes from the C2:Rev-erbE cell line relative to wild
type C2C12s (data not shown). Considering the efficient ex-
pression of the exogenousRev-erbEmRNA transcript (Fig. 3,
A and B), this data suggests that the endogenous transcript
expression is reduced, in concordance with the previous anal-
ysis of this cell line (29). The down-regulation of the endoge-
nous transcript is not surprising. During myogenesis, mRNA
pool sizes in muscle tissue are under strict control (31) and
mechanisms in skeletal muscle exist that sense total output
from exogenous and endogenous genes (32). Furthermore, ex-
ogenous expression of a number of different contractile protein
transgenes in the mouse (e.g. myosin light chain 2, troponin I
fast, skeletal and cardiac actin) results in the decline of the
expression of the corresponding endogenous gene (32–36).
Ectopic Rev-erbE mRNA expression does not affect the
mRNA expression level of the other member of the Rev-erb
family, Rev-erbA (Fig. 3E). Interestingly, the closely related
but opposingly acting orphan receptor, ROR, was dramati-
cally increased6-fold (Fig. 3F) in the C2:Rev-erbE cell line.
However, the levels of ROR- remain unchanged (see Table IV).
These data indicate that there is cross-talk between these two
related, but opposingly acting, orphan receptors in skeletal
muscle cells.
Dominant Negative Rev-erb Regulates the Expression of
Genes Involved in Lipid Absorption and Energy Expenditure—
The expression of many metabolic markers is altered during
skeletal muscle differentiation and acquisition of the muscle-
specific and contractile phenotype (Fig. 1). We therefore analyzed
the expression of the genes involved in differentiation and skel-
etal muscle metabolism in the C2:Rev-erbE cell line, relative
to wild-type C2C12 cells (see Table I and II). Before analysis of
the mRNAs encoding the metabolic enzymes we first character-
ized the key markers of differentiation in the C2:Rev-erbE cell
line to determine a threshold of significance with which to assess
putative changes in a relevant context.
We observed that after mitogen withdrawal, the C2:Rev-
erbE cells formed post-mitotic multinucleated myotubes and
thus had morphologically differentiated. The induction and
activation of myogenin (Fig. 3C) demonstrated that the cells
had also acquired a muscle-specific phenotype. Transcripts for
the contractile proteins troponin I slow ((Tnni1) Fig. 4A), and
troponin I fast ((Tnni2) (Fig. 4B)) were also induced after
serum withdrawal demonstrating that the C2:Rev-erbE cell
line had acquired a contractile phenotype and was biochemi-
cally differentiated. Analysis of the relative expression of these
biochemical markers in wild type C2C12 versus C2:Rev-erbE
myotubes after 4 days of serum withdrawal revealed that myo-
FIG. 3. Ectopic expression of the dominant negative Rev-erbE accelerates myogenesis and induces expression of ROR. Total
RNA was extracted from the wild type (C2C12) and the dominant negative (C2:Rev-erbE) cell lines from proliferating myoblasts (PMB), and
myotubes after 4 days of serum withdrawal (MT4), reverse transcribed to cDNA, and analyzed by Q-RT-PCR. Gene-specific primers were used to
examine the expression of: A and B, Rev-erbE; C, myogenin; D, -actin E, Rev-erb; F, ROR. Normalized expression is calculated relative to
the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (B) or 18 S rRNA (A, C–F) determined with the same cDNA. All
reactions were performed in triplicate and results are shown as average  S.D.
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genin (Fig. 3C) and fast type II (Tnni2) mRNA expression (Fig.
4, C and D) were increased 1.5–2-fold. The TNNI1 mRNA
encoding the slow type I isoform was actually slightly reduced.
This indicated that any major changes in the expression of
metabolic markers were not because of compromised morpho-
logical and/or biochemical differentiation. Moreover, these data
provide a threshold of significance whereby altered expression
of genes involved in skeletal muscle metabolism would only be
considered to be of importance if it varied more than 2-fold.
Analysis of the expression of the genes involved in skeletal
muscle metabolism in these cell lines revealed that attenuation
of Rev-erb had a number of significant effects in C2C12 cells
(Table II). In the context of lipid and fatty acid absorption we
observed repression of the mRNAs encoding Fabp-3 and -4 (5
and 24-fold) and Fat/Cd36 (5-fold) (Fig. 5, A–C). Analysis of
genes involved in the regulation of energy expenditure and
lipid utilization showed that the expression of Ucp3 mRNA
(Fig. 5D) was significantly repressed (7.5-fold). In contrast,
Ucp2 mRNA showed minimum changes in the cell line overex-
pressing Rev-erbE, relative to the 2-fold changes observed
in the markers of differentiation (Table II). Moreover, the
mRNA encoding Ampk3 (preferentially expressed in glycolytic
fast twitch muscle fibers), a regulator of glucose uptake, and
energy balance was unchanged by Rev-erbE expression. The
expression of Scd-1, a key enzyme involved in adiposity, is
repressed 4-fold in the cell line overexpressing Rev-erbE
(Fig. 5E). In contrast, the expression of mRNA encoding the
Scd-2 was relatively unaffected. Surprisingly, Srebp-1c mRNA
expression increased 2.8-fold (Fig. 5F, Table II).
The expression of the transcripts encoding Cpt1, Mcad, and
Acs-4 that are involved in lipid catabolism and preferential fuel
utilization were not affected in the Rev-erbE expressing cell
line (Table II). Additionally, we did not observe any changes in
the expression of mRNAs encoding ABCA1, ABCA8/G1, apoE,
Cav-3, and ADRP, which are involved in cholesterol homeosta-
sis and lipid storage (Table II). Analysis of the expression of
many other nuclear hormone receptors that have been demon-
strated to regulate lipid and carbohydrate metabolism, includ-
ing ERR, PPAR-, -/, and -, LXR and -, Rev-erb, and
Nur77 demonstrated that Rev-erbE expression did not affect
TABLE II
Relative changes in the expression of genes involved in
lipid metabolism in skeletal muscle cells
constitutively expressing Rev-erbE
Gene -Fold change
Fatty acid and lipid absorption
Fat/Cd36 25.4
Fabp-3 24.3
Fabp-4 224.4
Lipid catabolism
Lpl 22.1
Cpt-1 21.9
Cpt-2 21.8
Acs4 11.6
AdipoR1 21.2
AdipoR2 21.4
Pdk-2 21.8
Pdk-4 21.4
Mcad 21.1
Energy expenditure
Ucp3 27.5
Ucp2 21.8
Energy balance
Ampk1 11.7
Ampk1 21.0
Ampk3 21.4
Lipid efflux and homeostasis
Abca1 11.0
Abcg8 11.7
ApoE 22.0
Cav3 22.1
Lipid storage
Adrp 21.3
Lipogenesis
Srebp-1c 12.8
Scd-1 23.9
Scd-2 11.3
Fas 21.0
Contractility/myogenic markers
Tnni1 21.2
Tnni2 11.6
Myogenin 12.1
-Actin 11.4
FIG. 4. The C2:Rev-erbE cell line acquires contractile mark-
ers of skeletal muscle. A and B, expression of troponin I type I (slow;
Tnni1) and II (fast; Tnni2) mRNA levels, respectively, in the C2:Rev-
erbE cell line. Total RNA was extracted from proliferating myoblasts
(PMB) or myotubes were harvested after 4 days of serum withdrawal
(MT4), reverse transcribed to cDNA, and analyzed by Q-RT-PCR. Gene-
specific primers were used to examine the expression of Tnni1 (A) and
Tnni2 (B). C and D, total RNA was extracted from wild type (C2C12)
and dominant negative (C2:Rev-erbE) cell lines from myotubes after
4 days of serum withdrawal, reverse transcribed to cDNA, and analyzed
by Q-RT-PCR. Gene-specific primers were used to examine the expres-
sion of Tnni1 (C) and Tnni2 (D). Normalized expression was calculated
relative to the expression of 18S rRNA determined with the same
cDNA. All reactions were performed in triplicate and results are shown
as average  S.D.
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the expression of the mRNAs encoding these NRs (see
Table IV).
Rev-erb Modulates Myokine Expression—Muscle cytokines
(myokines) include IL-6, IL-15, and myostatin control inflam-
mation, energy expenditure, muscle growth, and fat deposition
(see Table I). The Rev-erb nuclear receptor has been impli-
cated in the control of inflammation, and the modulation of the
NFB-dependent pathway. Therefore, we decided to investi-
gate the expression of several myokines and inflammatory
markers/regulators in the wild-type and C2C12 cells express-
ing Rev-erbE.
Initially, we examined the expression of IL-6, IL-15, myosta-
tin, and IB (the regulator of NFB) during differentiation of
native C2C12 cells. We isolated total RNA from wild type
C2C12 proliferating myoblasts, and post-mitotic multinucle-
ated myotubes after 4 days of serum withdrawal, and analyzed
the expression levels of mRNAs by Q-RT-PCR. First, we ob-
served that these myokines, and modulators of the inflamma-
tory process, were expressed in wild type C2C12 cells (Fig. 6).
Second, we observed that IL-15 and myostatin were induced
(31- and 25-fold, respectively), whereas IB and IL-6 were
repressed (2.5- and 5.5-fold, respectively) during myogenic
differentiation (Fig. 6, A–D).
Subsequently, we examined the effect of Rev-erbE on
the expression of the myokines, and inflammatory regulators
in C2:Rev-erbE cells after 4 days of serum withdrawal,
relative to similarly differentiated native C2C12 cells by
Q-RT-PCR (see Table III). Interestingly, we observed that
ectopic expression of Rev-erbE leads to an induction in the
inhibitor of NFB-mediated gene expression, IB (Fig. 6E).
Consistent with increased expression of IB, mRNAs encod-
ing the NFB and tumor necrosis factor target genes IL-15
(Fig. 6G) and Cox-2 (Table III) were not induced in cells
expressing Rev-erbE.
Curiously, we found that IL-6 mRNA is robustly increased
(15-fold; Fig. 6F), and myostatin mRNA is dramatically re-
duced (24-fold; Fig. 6H) in the cells expressing Rev-erbE,
concordant with the precocious differentiation of the C2:Rev-
erbE cell line. In summary, this demonstrates that Rev-erb
regulates myokine expression, and as such is a critical modu-
lator of muscle growth and inflammation in this tissue.
DISCUSSION
We have utilized the C2C12 in vitro cell culture model sys-
tem and ectopic overexpression of dominant negative Rev-erb
to investigate the role of this orphan receptor in skeletal muscle
lipid, and energy homeostasis. Here we report that perturba-
tion of Rev-erb function decreases the expression of genes
involved in lipid absorption. Additionally, we observed dra-
matic induction and repression of two myokines, IL-6, and
myostatin, respectively, which are involved in energy expend-
iture, inflammation, muscle hypertrophy and hyperplasia, and
the accumulation of body fat.
These observations are consistent with genetic and molecu-
lar studies that demonstrate that the NR1D subfamily of nu-
clear receptors (Reverbs) has a direct role in lipid homeostasis.
For example, the NR1D subfamily of orphan receptors regulate
the expression of ApoC-III (20, 21), a major component of trig-
lyceride-rich remnant lipoprotein and associated with hyper-
triglyceridemia (37). In addition, Rev-erb / mice have ele-
vated levels of ApoC-III and very low density lipoprotein
triglycerides. Moreover, Rev-erb regulates ApoA1 gene ex-
pression in rodents treated with the hypolipidemic fibrate
drugs. Finally, Rev-erb is preferentially expressed in fast
twitch/type IIB glycolytic, and intermediate type IIA oxidative
fibers and null mutations lead to a transition to type I fibers
(38). This suggests that this orphan NR subgroup regulates
muscle fiber type, which can influence insulin sensitivity and
the utilization of aerobic/anaerobic metabolism for the genera-
tion of ATP.
Specifically, we demonstrated that attenuation of Rev-erb-
mediated gene expression suppresses the expression of a sub-
group of genes that include Fabp-3 and -4, Cd36, Ucp-3, and
Scd-1 that are involved in lipid absorption and utilization. In
this context, it is interesting to note that mice with a targeted
disruption of SCD-1, a key target for Rev-erb, had lower levels
of very low density lipoprotein, impaired triglyceride and cho-
lesterol ester biosynthesis, and a lean phenotype (39). The
Scd-1 / phenotype is very similar to the natural mutation
called staggerer (RORsg/sg) in an obese mouse strain, which
leads to a functional knockout of ROR. The staggerer mice
exhibit an aberrant blood-lipid profile with lower circulating
plasma levels of HDL-C, apoC-III, and plasma triglycerides. It
FIG. 5. Rev-erb controls genes that regulate lipid metabolism
and energy expenditure. Total RNA was extracted from wild type
(C2C12) and dominant negative (C2:Rev-erbE) cell lines from myo-
tubes after 4 days of serum withdrawal, reverse transcribed to cDNA,
and analyzed by Q-RT-PCR. Gene-specific primers were used to exam-
ine the expression of: A, Fabp-3; B, Fabp-4; C, Cd36; D,Ucp-3; E, Scd-1;
and F, Srebp1c. Relative expression is shown as -fold repression and
-fold activation calculated relative to the expression in the wild type
C2C12 cell line, which was arbitrarily set at 1. All reactions were
performed in triplicate and results are shown as average  S.D.
TABLE III
Relative changes in the expression of genes encoding myokines and
inflammatory markers in skeletal muscle cells constitutively
expressing Rev-erbE
Gene -Fold change
IL-6 115.1
IL-15 11.0
IB 12.8
NFB (relA) 11.0
Cox-2 21.3
Myostatin 223.7
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should be noted that a dominant negative ROR represses both
Rev-erb and -mRNA expression in skeletal muscle (16). More-
over, lack of Fabp4, a key target for Rev-erb in our model,
protected the mice deficient in ApoE against atherosclerosis (40).
Interestingly, we observed a suppression in the expression of
genes involved in lipid absorption, and in Scd-1 that is involved
in the formation of cholesterol esters. Moreover the activity of
Scd-1 has also been linked to adiposity. Curiously, we observed
an increase in Srebp-1c expression, the master regulator of
fatty acid metabolism. This apparent contradiction is in con-
cordance with several reports in the literature. For example,
Raspe et al. (15), showed that staggerer mice have reduced
plasma triglycerides, and Lau et al. (16) demonstrated that a
dominant negative ROR expression in muscle reduced
Srebp-1c mRNA expression. The increase in SREBP-1c expres-
sion correlates with the 5-fold increase in ROR mRNA ex-
pression in the C2:Rev-erbE cell line. Second, in most tissues
SREBP-1c and SCD-1 mRNA are coordinately expressed and
regulated. However, it has been previously reported in skeletal
muscle cells, and tissue treated with LXR agonists, that
Srebp-1c and Scd-1 mRNA expression are uncoupled, and not
co-ordinately regulated (23).
Our studies also demonstrate that Rev-erb has a crucial
role in regulating UCP3. Abundant expression of this gene
correlates with preferential lipid utilization, and increased en-
ergy expenditure. The role of uncoupling proteins in regulating
energy balance have been extensively investigated through
transgenic mice and cell culture studies (41–43). Repression of
UCP3 mRNA also correlates with the decreased expression of
genes involved in lipid absorption and utilization, in concord-
ance with the observations derived from this study.
Recent studies (22, 44, 45) have demonstrated a role of ROR
in the inflammation process. For example, ROR has an anti-
FIG. 6. Rev-erb regulates myokine
expression. Total RNA was isolated
from wild type C2C12 proliferating myo-
blasts (PMB) and post-mitotic multinucle-
ated myotubes after 4 days of serum with-
drawal (MT4), A–D, or wild type (C2C12)
and dominant negative (C2:Rev-erbE)
cell lines from myotubes after 4 days of
serum withdrawal (E–H). RNA was re-
verse transcribed to cDNA and analyzed
by Q-RT-PCR. Gene-specific primers were
used to examine the expression of: A and
E, IB; B and F, IL-6; C and G, IL-15;
and D and H, myostatin. Relative expres-
sion is shown as -fold repression and -fold
activation calculated relative to the ex-
pression in the wild type C2C12 cell line
that was arbitrarily set at 1. All reactions
were performed with at least triplicates
and results are shown as average  S.D.
TABLE IV
Relative changes in the expression of the nuclear hormone receptors in
skeletal muscle cells constitutively expressing Rev-erbE
Gene -Fold change
Rev-erb 11.5
Rev-erb 11.2
ROR 15.8
ROR 11.0
ERR 11.0
PPAR- 11.1
PPAR-/ 11.0
PPAR- 21.4
LXR 11.2
LXR 21.0
Nur77 11.8
NOR-1 11.0
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inflammatory role by inhibiting tumor necrosis factor--in-
duced gene expression (22). The molecular basis of this modu-
lation involves the direct induction of IB transcription,
thereby inhibiting the NFB signaling cascade. Conversely,
Rev-erb induces the NFB-mediated activation of the inflam-
matory cascade, for example, Cox-2 (44). Our studies show that
attenuation of Rev-erb-mediated gene regulation leads to el-
evated ROR and IB expression in skeletal muscle cells.
This correlates with no change in expression of the NFB/
tumor necrosis factor target genes, Cox-2 and IL-15.
Surprisingly, these studies have revealed a dramatic induc-
tion (15-fold) of interleukin-6, in the presence of increased
IB expression. However, IL-6 is an exercised induced myo-
kine that induces lipolysis in adipose tissue, and suppresses
tumor necrosis factor production. The increased expression of
IL-6 is consistent with decreased myostatin expression. For
example, it has been reported that IL-6 deficiency leads to
late-onset obesity (46), whereas myostatin deficiency leads to
the reduced accumulation of body fat (47). Therefore, the in-
verse correlation between IL-6 andmyostatin expression in our
Rev-erb cell line is in concordance with the phenotypic effects
of these myokines on metabolism (48–50). The study has im-
plicated Rev-erb in the regulatory cascade controlling genes
involved in lipid homeostasis. Furthermore, the significant im-
pact on myokine expression that regulates inflammation, lipol-
ysis, muscle growth, and the accumulation of body fat under-
scores the potential therapeutic utility of Rev-erb modulation
by inverse agonists/antagonists. However, identification of
small molecule regulators will be hindered by the lack of a
significant pocket in the ligand binding domain in the Rev-erb/
NR1D subgroup of orphan nuclear receptors (51).
It is becoming increasingly apparent that skeletal muscle is
a critical target tissue in the fight against metabolic disorders
associated with diet, lifestyle, and metabolism. For example,
LXR, PPAR, -/, and - in skeletal muscle have been shown
to be involved in enhancing the insulin-stimulated glucose
disposal rate, decreasing triglycerides, increasing energy ex-
penditure, and increasing lipid catabolism, cholesterol efflux,
and plasma HDL-C levels (14, 23–28).
Activation of these NRs in muscle has lead to increased
insulin sensitivity, resistance to diet-induced obesity, and ath-
erosclerosis. Hence, orphan nuclear receptors (for example,
Rev-erb) that regulate lipid homeostasis and inflammation in
skeletal muscle have enormous homeostatic ramifications. As
discussed, skeletal muscle is a major mass peripheral tissue,
and this lean tissue accounts for 40% of the total body mass
(36% for females, and 42% for males) and 30–50% of the energy
expenditure. These results indicate significant homeostatic in-
terrelationships between the muscular and other body systems
including the cardiovascular, endocrine, and lymphatic net-
works for the treatment of dyslipidemia, syndrome X, and
inflammation. In conclusion, we suggest that in skeletal muscle
cells, Rev-erb programs a cascade of gene expression that
controls the regulatory cross-talk between lipid metabolism
and inflammation.
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